cd38

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and extracellular enzyme CD38 in malignant cells of the hematological system, a highly expressed protein in multiple myeloma. It exhibits antitumor activity, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent cytophagocytosis, directly inducing apoptosis without crosslinking. Isatuximab inhibits CD38 extracellular enzyme activity, affecting various cellular functions.

Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants.

Erzotabart, an IgG1-kappa monoclonal antibody targeting CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) in Homo sapiens, exhibits antineoplastic activity [1].

Daratumumab is a human monoclonal antibody that targets CD38 a cell surface protein that is overexpressed on multiple myeloma MM) cells.

Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment of relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] [2] [3].

Modakafusp alfa (TAK-573) is a humanized anti-CD38 IgG4 monoclonal antibody fused with 2 attenuated IFNα2b molecules, being researched for potential use in treating multiple myeloma [1].